Quick Search 
Drugs of the Future
Register or sign in

  
 
  
Drugs Fut 2018, 43(8): 581
ISSN 0377-8282
e-ISSN 2013-0368
Copyright 2018 Clarivate
CCC: 0377-8282
DOI: 10.1358/dof.2018.043.08.2847832
 
 
Anxiolytic properties of cannabidiol
Meireles da Fonseca, G.E., Vieira-Coelho, M.A.
 
 
Cannabidiol (CBD) is a nonintoxicating compound present in the Cannabis sativa plant and evidence of its therapeutic utility is increasing. In fact, CBD is already being used as therapy in various neurologic conditions and other potential usages are under investigation. The aim of this review is to summarize current knowledge on CBD’s usefulness as a therapeutic agent in anxiety disorders. The cannabinoid’s anxiolytic profile has been demonstrated in different rodent models as well as in humans, the first proof consisting of its ability to reverse delta-9-tetrahydrocannabinol (THC)-induced anxiety. Although recent experiments suggest CBD does not reduce emotional responses to negative stimuli, a large body of evidence argues the compound is anxiolytic in several anxiety models. CBD’s actions seem mainly mediated via 5-HT1A receptor potentiation and the cannabinoid is also thought to partially act through interaction with the endocannabinoid system, possibly by inhibiting anandamide’s metabolism. Moreover, neuroimaging studies have put forward that CBD specifically acts on limbic and paralimbic brain areas. Lastly, CBD is known to activate the anxiogenic transient receptor potential vanilloid receptor 1 (TRPV1), which may explain its inverted U-shape dose-response curve. Considered generally safe, this cannabinoid embodies a promising anxiolytic agent.


Full Text: PDF 
 
  



© Clarivate. All rights reserved.
Copyright NoticeTerms of UsePrivacy StatementCookie PolicyManage cookie preferences